Inconsistent results across regions have been reported in a number of recent large trials. In this research, by reviewing results from studies that showed inconsistent treatment effects, and summarizing lessons learned, we provide some recommendations for minimizing the chance of inconsistency and allowing more accurate interpretation when such signs of heterogeneity arise, for example: keep the number of regions for consistency evaluation at a minimum to avoid observing false inconsistency signals; proactively address in the protocol the differences in culture, medical practices, and other factors that are potentially different across regions; closely monitor the blinded data from early-enrolled patients to more effectively identify and address issues such as imbalance of baseline covariates or inconsistency of primary outcome rates across regions. For treatments of life-threatening conditions, the stakes for accurate interpretation of MRCT results are high; the criteria for decisions warrant careful consideration.
MHLW (Ministry of Health, Labour and Welfare of Japan). Basic principles on global clinical trials 2007. http://www.pmda.go.jp/files/000153265.pdf. Accessed November 14, 2015.
3.
QuanHLiMChenJ. Assessment of consistency of treatment effects in multiregional clinical trials. Drug Inf J. 2010;44:617–632.
4.
ChenJQuanHBinkowitzB. Assessing consistent treatment effect in a multi-regional clinical trial: a systematic review. Pharm Stat. 2010;9:242–253.
5.
LiGChenJQuanHShentuY. Consistency assessment with global and bridging development strategies in emerging markets. Contemp Clin Trials. 2013;36(2):687–696.
6.
TanakaYLiGWangYChenJ. Qualitative consistency of treatment effects in multiregional clinical trials. J Biopharm Stat. 2012;22:988–1000.
7.
PittBPfefferMAAssmannSF. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370:1383–1392.
8.
PfefferMAClaggettBAssmannSF. Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) Trial. Circulation. 2015;131(1):34–42.
9.
BristowMREncisoJSGershBJ. Detection and management of geographic disparities in the TOPCAT trial: lessons learned and derivative recommendations. JACC Basic Transl Sci. 2016;1(3):180–189.
10.
de DenusSO’MearaEDesaiAS. Spironolactone metabolites in TOPCAT—new insights into regional variation. N Engl J Med. 2017;376:1690–1692.
11.
GiacconeGHerbstRSManegoldC. Gefitinib in combination with gemcitabine and cisplatin in advanced non–small-cell lung cancer: a phase III trial—INTACT 1. J Clin Oncol2004;22:777–784.
12.
HerbstRSGiacconeGSchillerJH. Gefitinib in combination with paclitaxel and carboplatin in advanced non–small-cell lung cancer: a phase III trial - INTACT 2. J Clin Oncol2004;22:785–794.
ThatcherNChangAParikhP. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005;366:1527–1537.
16.
MaemondoMInoueAKobayashiK. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362(25):2380–2388.
CohnJNArchibaldDGZiescheS. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. N Engl J Med. 1986;314:1547–1552.
21.
CohnJNJohnsonGZiescheS. A comparison of enalapril with hydralazine–isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325:303–310.
22.
CarsonPZiescheSJohnsonGCohnJN. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. J Card Fail. 1999;5:178–187.
ExnerDVDriesDLDomanskiMJCohnJN. Lesser response to angiotensin-converting-enzyme inhibitor therapy in blacks as compared with white patients with left ventricular dysfunction. N Engl J Med. 2001;344 (18):1351–1357.
25.
CohnJNTognoniG. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667–1675.
26.
WallentinLBeckerRCBudajA. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045–1057.
27.
CarrollKJFlemingTR. Statistical evaluation and analysis of regional interactions: the PLATO trial case study. Stat Biopharm Res. 2013;5(2):91–101.
WedelHDeMetsDDeedwaniaP. Challenges of subgroup analyses in multinational clinical trials: experiences from the MERIT-HF trial. Am Heart J2001;142(3):502–511.
34.
QuanHMaoXTanakaY. Example-based illustrations of design, conduct, analysis and result interpretation of multi-regional clinical trials. Contemp Clin Trials. 2017;58:13–22.
YusufSSleightPEPogueJFBoschJDaviesRDagenaisG. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342(3):145–153.
37.
ArnoldJMYusufSYoungJ. Prevention of heart failure in patients in the Heart Outcomes Prevention Evaluation (HOPE) study. Circulation. 2013;107(9):1284–1290.
38.
YusufSWittesJ. Interpreting geographic variations in results of randomized, controlled trials. N Engl J Med. 2016;375(23):2263–2271.
39.
BaselgaJCortésJKimSB. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366:109–119.
SwainSMKimSBCortésJ. Overall survival benefit with pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer in CLEOPATRA, a randomised Phase 3 study. Lancet Oncol. 2013;14(6):461–471.
MAGIC Investigators. Early administration of magnesium to high risk patients with acute myocardial infarction in the Magnesium in Coronaries (MAGIC) trial: a randomized, controlled trial. Lancet. 2002;360:1189–1196.
47.
DomanskiMAntmanEMcKinlayS. Geographic variability in patient characteristics, treatment and outcome in an international trial of magnesium in acute myocardial infarction. Control Clin Trials2004;25:553–562.
48.
HillAB. The environment and disease: association or causation. Proc R Soc Med1965;58(5):295–300.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
